Comparison of the roche cobas® 4800 HPV assay to roche amplicor for detection of high-risk human papillomavirus

S. Phillips; A. M. Cornall; D. A. Machalek; S. M. Garland; D. Bateson; M. Garefalakis; S. N. Tabrizi

doi:10.1007/s10096-016-2665-1

Comparison of the roche cobas® 4800 HPV assay to roche amplicor for detection of high-risk human papillomavirus

S. Phillips, A. M. Cornall, D. A. Machalek, S. M. Garland, D. Bateson, M. Garefalakis, S. N. Tabrizi

Research output: Contribution to journal › Article › Research › peer-review

7 Citations (Scopus)

Abstract

Roche Amplicor HPV (AMP) had previously been used for detection of high-risk human papillomavirus (HR-HPV) in epidemiological and clinical studies. As this assay is no longer available, we compared its performance using PreservCyt samples from women aged of 18–24 years attending for routine cervical cytology screening to Roche Cobas® 4800 (Cobas) to determine if subsequent studies could continue using the Cobas assay. Overall 507 samples were tested on Cobas and compared to previous AMP results, with discrepant samples tested on Roche Linear Array. Results: Overall, agreement between the Cobas and AMP for the presence of HR HPV types was very high (κ = 0.81) (95 % CI: 0.76 - 0.87) with percentage agreement of 91.57 %. Cobas is comparable to AMP for the detection of HR-HPV types in a community recruited cohort of healthy women.

Original language	English
Pages (from-to)	1305-1307
Number of pages	3
Journal	European Journal of Clinical Microbiology and Infectious Diseases
Volume	35
Issue number	8
DOIs	https://doi.org/10.1007/s10096-016-2665-1
Publication status	Published - 13 May 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

family planning clinic
discrepant sample
roche linear array
cobas testing
attend family planning clinic

Access to Document

10.1007/s10096-016-2665-1

Cite this

@article{eb41a9d5afa445d0a971b5c424963f79,

title = "Comparison of the roche cobas{\textregistered} 4800 HPV assay to roche amplicor for detection of high-risk human papillomavirus",

abstract = "Roche Amplicor HPV (AMP) had previously been used for detection of high-risk human papillomavirus (HR-HPV) in epidemiological and clinical studies. As this assay is no longer available, we compared its performance using PreservCyt samples from women aged of 18–24 years attending for routine cervical cytology screening to Roche Cobas{\textregistered} 4800 (Cobas) to determine if subsequent studies could continue using the Cobas assay. Overall 507 samples were tested on Cobas and compared to previous AMP results, with discrepant samples tested on Roche Linear Array. Results: Overall, agreement between the Cobas and AMP for the presence of HR HPV types was very high (κ = 0.81) (95 \% CI: 0.76 - 0.87) with percentage agreement of 91.57 \%. Cobas is comparable to AMP for the detection of HR-HPV types in a community recruited cohort of healthy women.",

keywords = "family planning clinic, discrepant sample, roche linear array, cobas testing, attend family planning clinic",

author = "S. Phillips and Cornall, \{A. M.\} and Machalek, \{D. A.\} and Garland, \{S. M.\} and D. Bateson and M. Garefalakis and Tabrizi, \{S. N.\}",

year = "2016",

month = may,

day = "13",

doi = "10.1007/s10096-016-2665-1",

language = "English",

volume = "35",

pages = "1305--1307",

journal = "European Journal of Clinical Microbiology and Infectious Diseases",

issn = "0934-9723",

publisher = "Springer-Verlag London Ltd.",

number = "8",

}

TY - JOUR

T1 - Comparison of the roche cobas® 4800 HPV assay to roche amplicor for detection of high-risk human papillomavirus

AU - Phillips, S.

AU - Cornall, A. M.

AU - Machalek, D. A.

AU - Garland, S. M.

AU - Bateson, D.

AU - Garefalakis, M.

AU - Tabrizi, S. N.

PY - 2016/5/13

Y1 - 2016/5/13

N2 - Roche Amplicor HPV (AMP) had previously been used for detection of high-risk human papillomavirus (HR-HPV) in epidemiological and clinical studies. As this assay is no longer available, we compared its performance using PreservCyt samples from women aged of 18–24 years attending for routine cervical cytology screening to Roche Cobas® 4800 (Cobas) to determine if subsequent studies could continue using the Cobas assay. Overall 507 samples were tested on Cobas and compared to previous AMP results, with discrepant samples tested on Roche Linear Array. Results: Overall, agreement between the Cobas and AMP for the presence of HR HPV types was very high (κ = 0.81) (95 % CI: 0.76 - 0.87) with percentage agreement of 91.57 %. Cobas is comparable to AMP for the detection of HR-HPV types in a community recruited cohort of healthy women.

AB - Roche Amplicor HPV (AMP) had previously been used for detection of high-risk human papillomavirus (HR-HPV) in epidemiological and clinical studies. As this assay is no longer available, we compared its performance using PreservCyt samples from women aged of 18–24 years attending for routine cervical cytology screening to Roche Cobas® 4800 (Cobas) to determine if subsequent studies could continue using the Cobas assay. Overall 507 samples were tested on Cobas and compared to previous AMP results, with discrepant samples tested on Roche Linear Array. Results: Overall, agreement between the Cobas and AMP for the presence of HR HPV types was very high (κ = 0.81) (95 % CI: 0.76 - 0.87) with percentage agreement of 91.57 %. Cobas is comparable to AMP for the detection of HR-HPV types in a community recruited cohort of healthy women.

KW - family planning clinic

KW - discrepant sample

KW - roche linear array

KW - cobas testing

KW - attend family planning clinic

UR - https://www.scopus.com/pages/publications/85027941649

U2 - 10.1007/s10096-016-2665-1

DO - 10.1007/s10096-016-2665-1

M3 - Article

C2 - 27177752

AN - SCOPUS:85027941649

SN - 0934-9723

VL - 35

SP - 1305

EP - 1307

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

IS - 8

ER -

Comparison of the roche cobas® 4800 HPV assay to roche amplicor for detection of high-risk human papillomavirus

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this